Buy mediocre company, strategy of add-on acquisition?

In a deal that recently went through, my client [PE firm] completed a transaction. Based on my MBB firm's due diligence, it seems like a pretty terrible company. 

We flagged to them some of the risks associated with the transaction—-none of which they were previously aware of—-and that the TAM is decreasing by 3-4% every year. 

In spite of that, they went through with the transaction, and are now pursuing a buy-and-build strategy


My questions: 

  1. Is it common to buy mediocre companies specifically for the purposes of add-on acquisitions? (PE client is not a distressed buyer)

  2. Any recommendations whether or not on a deal walkthrough, I should concur with the PE firms' decision (i.e., "I agree with this decision. Despite the risks, the company has strong cash flow profile, long-term contracts, and can make accretive acquisitions in this fragmented industry", or dissent? (i.e., "Personally, I disagree with this decision. The market headwinds are too strong for me to ignore. Even if we pursue a buy-and-build strategy, the core of our business remains in a declining market")

  3. Frankly, even if you buy-and-build, the core of the business is still going to be sh*t. And what strategic buyer is going to want to buy portco a dying industry. Any thoughts? 

 
Most Helpful

Not enough data. How good of a deal, in $ terms, did they get? If you buy a mediocre company for the price of a shit company then you just made a killer deal because it won't take you even a year to fix the company and now you will be able to sell it for much more. If you buy a mediocre company, for the price of a good company, then you just fucked yourself right in the ass because best you can do is turn it into an actual good company for which no one will be willing to pay more than you did.

Given that we are mid-recession, I assume it is the former. TBH buying a mediocre company when valuation multiples are down the shitter is a genius move because all you have to do is wait a few years (which you would have done anyways) to sell at the new top the moment JPow starts printing money like a maniac again like he usually does.

 

I'm a MBB consultant. I don't know the exact terms of the deal. But as I wrote, TAM is declining 3-4% every year. This is out of the control of the target / portco—-it's simply a declining industry. 

Their strategy is clearly buy-and-build, and already they have acquired a number of add-on acquisitions in adjacencies that are more attractive. But even if they were going to pursue this add-on strategy, couldn't they have bought a less sh*tty platform company

In 5 years, they'll still have a sh*tty base company, in a declining market, with a few nicer add-ons. Is it worth it? IDK. But if I'm going to walkthrough this deal, I need to figure out what to say

 

Very sector dependent but I get the sense the whole buy and build model is going to blow up in a lot of GPs faces (namely HC) as the market is saturated with buyers up and down the size spectrum.  Know several people who work directly for these platforms in HC and they can't buy a single company because A. they now know what they're really worth so can't low ball them for 3x EBITDA on a medical practice, and B. they don't want PE touching their business.  Just my 2 cents but given this GPs are going to have to buy shittier platforms which will lead to problems down the road.

  8.3.4
 

Nihil consequatur qui sunt minus quas. Quibusdam sed quia consequuntur consectetur nam occaecati est soluta. Maxime non magni quisquam.

Assumenda sit iste vero at fugiat officiis itaque. Ut ut et atque dolores sed vitae iusto amet. Quia voluptatum quis autem qui. Possimus autem est voluptas et totam eos. Nostrum perferendis soluta vel distinctio. Quia praesentium id vel sequi quia eius quaerat.

In laboriosam eos corrupti voluptatem blanditiis eius ratione. Laborum optio possimus laudantium. Consequatur odio sed odit sit non in ad. Autem ut magni quos adipisci id nobis voluptatem. Perferendis porro accusamus aliquid quas labore cumque sunt recusandae.

Career Advancement Opportunities

April 2024 Private Equity

  • The Riverside Company 99.5%
  • Blackstone Group 99.0%
  • Warburg Pincus 98.4%
  • KKR (Kohlberg Kravis Roberts) 97.9%
  • Bain Capital 97.4%

Overall Employee Satisfaction

April 2024 Private Equity

  • The Riverside Company 99.5%
  • Blackstone Group 98.9%
  • KKR (Kohlberg Kravis Roberts) 98.4%
  • Ardian 97.9%
  • Bain Capital 97.4%

Professional Growth Opportunities

April 2024 Private Equity

  • The Riverside Company 99.5%
  • Bain Capital 99.0%
  • Blackstone Group 98.4%
  • Warburg Pincus 97.9%
  • Starwood Capital Group 97.4%

Total Avg Compensation

April 2024 Private Equity

  • Principal (9) $653
  • Director/MD (22) $569
  • Vice President (92) $362
  • 3rd+ Year Associate (91) $281
  • 2nd Year Associate (206) $266
  • 1st Year Associate (387) $229
  • 3rd+ Year Analyst (29) $154
  • 2nd Year Analyst (83) $134
  • 1st Year Analyst (246) $122
  • Intern/Summer Associate (32) $82
  • Intern/Summer Analyst (314) $59
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
Betsy Massar's picture
Betsy Massar
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
kanon's picture
kanon
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
Jamoldo's picture
Jamoldo
98.8
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”